The Goldman Sachs Group Lowers Moderna (NASDAQ:MRNA) Price Target to $99.00

Moderna (NASDAQ:MRNA) had its price objective lowered by The Goldman Sachs Group from $112.00 to $99.00 in a research report report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities analysts also recently weighed in on MRNA. Wolfe Research initiated coverage on shares of Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 target price on the stock. UBS Group dropped their target price on shares of Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Evercore ISI reduced their price target on Moderna from $60.00 to $50.00 and set an “in-line” rating for the company in a report on Monday. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Finally, Barclays dropped their price target on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Four investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Moderna has an average rating of “Hold” and a consensus price target of $67.26.

Moderna Trading Up 0.8 %

Shares of NASDAQ:MRNA opened at $41.04 on Tuesday. The company’s 50-day moving average price is $40.87 and its two-hundred day moving average price is $62.03. Moderna has a one year low of $31.94 and a one year high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The stock has a market capitalization of $15.79 billion, a PE ratio of -7.05 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.39) earnings per share. On average, equities analysts forecast that Moderna will post -9.27 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 2,664 shares of company stock worth $115,210 over the last three months. Corporate insiders own 15.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of MRNA. Allworth Financial LP increased its position in Moderna by 17.3% during the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock worth $73,000 after purchasing an additional 281 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of Moderna by 140.1% during the fourth quarter. Blue Trust Inc. now owns 1,755 shares of the company’s stock worth $73,000 after buying an additional 1,024 shares in the last quarter. AustralianSuper Pty Ltd lifted its stake in shares of Moderna by 14.3% in the 4th quarter. AustralianSuper Pty Ltd now owns 16,584 shares of the company’s stock valued at $690,000 after acquiring an additional 2,077 shares during the last quarter. V Square Quantitative Management LLC boosted its holdings in shares of Moderna by 38.0% during the 4th quarter. V Square Quantitative Management LLC now owns 7,797 shares of the company’s stock valued at $324,000 after acquiring an additional 2,148 shares in the last quarter. Finally, Vontobel Holding Ltd. grew its position in Moderna by 122.6% during the 4th quarter. Vontobel Holding Ltd. now owns 258,368 shares of the company’s stock worth $10,743,000 after acquiring an additional 142,280 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.